- The Serum Institute of India will begin its new vaccine, Covovax, by June this year.
- The new vaccine which SII is producing is in cooperation with Novovax.
- Novavax had declared its alliance with SII to provide 2 billion doses of the Covid-19 vaccine.
TheNewsDesk, Pune: The Serum Institute of India (SII) has planned to begin its new vaccine, Covovax, by June this year. It could bring a large boost to the continuous Covid-19 vaccination drive in India,
On Saturday, SII CEO Adar Poonawalla stated that its partnership for a Covid-19 vaccine with Novavax had exhibited remarkable efficiency results.
The new vaccine shall be launched under the brand name of Covovax, which SII is producing in cooperation with Novovax. The Pune-based global vaccine giant has sought approval from the DCGI to commence domestic tests of the new product.
The development comes close on the heels of US-based biotechnology company Novavax proclaiming that its vaccine is 89.3 percent efficient in inhibiting Covid-19 in a test carried in the UK.
The study evaluated the effectiveness of the vaccine — NVX-CoV2373 — during a period with high transmission and a new UK variant strain of the virus emerging and travelling widely.
Stanley C. Erck, President and Chief Executive Officer, Novavax, stated, “NVX-CoV2373 has the potential to play an important role in solving this global public health crisis. We look forward to continuing to work with our partners, collaborators, investigators and regulators around the world to make the vaccine available as quickly as possible.”
Last year, Novavax had declared its alliance with SII to provide 2 billion doses of Covid-19 vaccine.
Source-Times Of India
